RxDoctor Payments Data

Brian Bennett, MD

Internal Medicine · Auburn, NYNPI 1477501609

Payments from drug & device makers

$1,063in general payments, 2019–2025

Across 58 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$318
  • AbbVie$107
  • Pfizer$85
  • GSK$80
  • Sumitomo Pharma America, Inc.$49
  • Amgen$42
  • plus $383 from 16 others

What the payments were for

  • Food & beverage$96391%
  • Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,063 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$312,437
Medicare patients
639
Services billed
10,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$201,507
OzempicSemaglutide132$178,077
JardianceEmpagliflozin91$132,538
TrulicityDulaglutide63$107,864
XareltoRivaroxaban52$68,412
JanuviaSitagliptin Phosphate58$59,011
MounjaroTirzepatide34$44,828
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$44,378
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr75$40,046
MyrbetriqMirabegron30$33,083
FarxigaDapagliflozin Propanediol29$27,302
Tresiba Flextouch U-100Insulin Degludec28$21,608
EntrestoSacubitril/Valsartan14$20,507
Breo ElliptaFluticasone/Vilanterol46$19,363
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$15,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$201,507193 claims
Novo NordiskOzempic, Novolog$37$183,578152 claims
Lilly USA, LLCTrulicity, Mounjaro$25$152,69297 claims
Boehringer IngelheimJardiance, Spiriva Respimat$26$139,421104 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$80$103,787180 claims
Johnson & JohnsonXarelto$21$68,41252 claims
MerckJanuvia, Dulera$12$64,12574 claims
AstraZenecaFarxiga, Breztri Aerosphere$35$39,21446 claims
Astellas Pharma US IncMyrbetriq$318$33,08330 claims
AbbVieSavella, Synthroid$107$12,91883 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$8,540564 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Auburn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →